Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Open-label, Single-arm Study Evaluating the Efficacy, Safety and Tolerability of Lerapolturev (PVSRIPO) and the Immune Checkpoint Inhibitor Pembrolizumab in the Treatment of Patients With Recurrent Glioblastoma

NCT04479241 is registered in ClinicalTrials.gov with Istari Oncology, Inc. as lead sponsor.

NCT NCT04479241
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04479241 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Open-label, Single-arm Study Evaluating the Efficacy, Safety and Tolerability of Lerapolturev (PVSRIPO) and the Immune Checkpoint Inhibitor Pembrolizumab in the Treatment of Patients With Recurrent Glioblastoma
Lead sponsor
Istari Oncology, Inc.
Phase
Phase 2
Overall status
Completed
Start date
October 21, 2020
Completion date
June 21, 2024
Enrollment
25 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

brain tumor, glioblastoma, recurrent glioblastoma, supratentorial glioblastoma